早期非小细胞肺癌免疫检查点抑制的现状
免疫检查点抑制(ICI)已革新转移性非小细胞肺癌(NSCLC)治疗,PD-1/PD-L1抗体较传统化疗反应率更高、总生存更优且耐受性更好。ICI已从二线移至一线,并正在不可切除III期(同步放化疗后度伐利尤单抗)和完全切除早期NSCLC的辅助/新辅助治疗中探索。立体定向消融放疗为不适合手术者提供替代,但其与ICI联合的数据几乎空白,早期小样本可行性研究结果有前景,需设计良好的III期试验探索。
要点
- PD-1/PD-L1抗体较传统化疗反应率更高、总生存更优且耐受性更好。
- 不可切除III期NSCLC同步放化疗后度伐利尤单抗改善2年无进展生存和总生存。
- 完全切除早期NSCLC复发以全身为主,大量辅助/新辅助ICI研究正在进行。
核心结论
- ICI已革新转移性NSCLC治疗,并正在早期NSCLC中探索以提高长期总生存和治愈率。
- 不可切除III期NSCLC同步放化疗后度伐利尤单抗带来2年无进展生存和总生存重大改善,有望提高治愈率。
- 完全切除早期NSCLC复发以全身为主,对整合ICI治疗寄予厚望,大量辅助或新辅助ICI研究正在进行。
- 立体定向消融放疗与系统治疗联合数据几乎空白,但联合放疗与ICI有强生物学依据,早期小样本可行性研究结果有前景,需设计良好的III期试验探索。
研究设计与样本
- 本文为综述,讨论早期非小细胞肺癌免疫检查点抑制的现状及正在进行的研究。
主要发现
- PD-1/PD-L1抗体较传统细胞毒化疗反应率更高、总生存更优且耐受性更好。
- ICI已从二线移至一线用于许多非致癌基因依赖NSCLC患者,单用或联合化疗。
- 不可切除III期NSCLC同步放化疗后度伐利尤单抗在2年无进展生存和总生存方面带来重大改善。
- 完全切除早期NSCLC复发模式以全身为主。
- 立体定向消融放疗为不适合或不愿手术者提供有效替代治疗。
局限性
- 联合系统治疗与立体定向消融放疗的数据几乎空白。
- 早期小样本可行性研究结果有前景,需在设计良好的III期试验中探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint inhibition (ICI) immunotherapy has revolutionized the approach to metastatic non-small-cell lung cancer (NSCLC). In particular, antibodies blocking the inhibitory immune checkpoints programmed death 1 (PD-1) and its ligand (PD-L1) are associated with higher response rates, improved overall survival and better tolerability as compared with conventional cytotoxic chemotherapy. Recently, ICI has moved from the second-line to the first-line setting for many patients with non-oncogene-addicted NSCLC, either alone or in combination with chemotherapy. The next logical step is to examine this therapy in patients with non-metastatic NSCLC to improve long-term overall survival and cure rates. For patients with unresectable stage III NSCLC, ICI with durvalumab after concurrent chemoradiotherapy has brought a major improvement in 2-year progression-free and overall survival, which holds promise for an improved cure rate. As the relapse pattern in patients with completely resected early-stage NSCLC is predominantly systemic, high expectations rest on the integration of ICI therapy in their treatment approach. A large number of studies with adjuvant or neo-adjuvant ICI are ongoing and will be discussed here. The advent of stereotactic ablative radiotherapy has brought a valid alternative treatment of patients unfit for or not willing to undergo surgery. Data on combining systemic therapy and stereotactic ablative radiotherapy are virtually non-existent, but there is a strong biological rationale to combine radiotherapy and ICI therapy. Early findings in small feasibility studies are promising and now need to be explored in well-designed phase III trials.
引用
- Vansteenkiste J, Wauters E, Reymen B, et al. Current status of immune checkpoint inhibition in early-stage NSCLC. Ann Oncol. 2019. PMID: 31143921. doi:10.1093/annonc/mdz175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。